INmune Bio Establishes Global Commercialization Framework for Ebstrocelâ„¢ Through Strategic Agreement with Uniphar
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into...
<![CDATA[Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks]]>
Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Sc...
Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Sec...
Inspire (INSP) Q3 2026 Earnings Call Transcript
Reimbursement headwinds cut Q3 revenue, but 2027 outlook improves.
Inspired (INSE) Q3 2026 Earnings Call Transcript
Regulatory headwinds hit results, but digital growth lifted margins.
<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>
<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>
INVI MindHealth Collaborates with Baylor College of Medicine and The Menninger Clinic to Assess Objective Biomarkers for...
Participating sites will use INVI's platform to capture and integrate longitudinal data across emerging mental health interventions HOUSTON, Nov. 2, 2026 /PRNewswire-PRWeb/ -- INVI...
Immatics: A Slow Event Clock And A Proven Market Make The SUPRAME Setup Better Than It Looks
Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Sec...
<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWall...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.